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REGULAR ARTICLE
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alone induces killing of
ENKTL and CAEBV
cells but is most effec-
tive when MCL-1 is
additionally targeted.
Epstein-Barr virus (EBV)–associated T- and natural killer (NK)–cell malignancies, such as
extranodal NK-/T-cell lymphoma (ENKTL), exhibit high chemoresistance and, accordingly,
such patients have a poor prognosis. The rare nature of such cancers and nonmalignant
T/NK lymphoproliferative disorders, such as chronic active EBV (CAEBV), has limited our
understanding of the pathogenesis of these diseases. Here, we characterize a panel of
ENKTL- and CAEBV-derived cell lines that had been established from human tumors to be
used as preclinical models of these diseases. These cell lines were interleukin-2 dependent
and found to carry EBV in a latency II gene-expression pattern. All cell lines demonstrated
resistance to cell death induction by DNA damage–inducing agents, the current standard of
care for patients with these malignancies. This resistance was not correlated with the
function of the multidrug efflux pump, P-glycoprotein. However, apoptotic cell death could
be consistently induced following treatment with A-1331852, a BH3-mimetic drug that
specifically inhibits the prosurvival protein BCL-XL. A-1331852–induced apoptosis was most
efficacious when prosurvival MCL-1 was additionally targeted, either by BH3-mimetics or
genetic deletion. Xenograft models established from the ENKTL cell line SNK6 provided
evidence that A-1331852 treatment could be therapeutically beneficial in vivo. The data here
suggest that therapeutic targeting of BCL-XL would be effective for patients with EBV-driven
T/NK proliferative diseases, however, MCL-1 could be a potential resistance factor.
Introduction
Extranodal natural killer (NK)–/T-cell lymphoma (ENKTL) is an aggressive malignancy predominantly
presenting within the upper aerodigestive tract as a highly necrotic tumor with invasion into local tissue.1
ENKTL is a relatively rare disease but found with a higher frequency in eastern Asia and South America
(4% to 6% of non-Hodgkin lymphomas) compared with western populations (0.5% of non-Hodgkin
lymphomas).2 Chemotherapy regimens for ENKTL, such as cyclophosphamide, hydroxydaunorubicin,
vincristine, prednisone (CHOP), are largely ineffective, yielding a median patient survival of only
7.8 months.3 Such poor effectiveness of CHOP in ENKTL has been attributed to expression and
function of the multidrug efflux pump, P-glycoprotein/MDR1.4,5 Accordingly, a new chemotherapy
regimen with theoretically reduced MDR1 susceptibility (dexamethasone, methotrexate, ifosfamide,
L-asparaginase, etoposide [called SMILE]) has been developed and has shown promise in early small
cohort studies.6-8 Of note, severe and prolonged cases of an Epstein-Barr virus (EBV)–driven nonmalignant
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T/NK-cell proliferative disease, called chronic active EBV (CAEBV),
can occasionally progress into ENKTL.9 Here, chemotherapy can
only be effective when combined with hematopoietic stem cell
transplantation during early stages of disease.10,11
ENKTLs are typically NK cell in origin, although a minority of cases
are of T-cell lineage, with a characteristic immunophenotype of
CD21, CD561, and cytoplasmic CD3e1 but surface CD32.12-14
Disease etiology is poorly understood but deletions at chromosome
6p21-q25 are the most frequent chromosomal abnormality in ENKTL
(40% to 50% of cases based on small patient studies15,16). The main
target of this deletion is thought to be the transcriptional repressor
PRDM1 but consistent genetic drivers of disease are yet to be
identified.15 In CAEBV, however, a study of 80 patient samples
identified mutations in the tumor repressor DDX3X as the most
common disease driver with a mutation frequency of 17.5%.17 A
confounding factor is that, in 100% of ENKTL cases, the malignant
cells are infected with EBV, a principally B-lymphotropic herpesvi-
rus. This requisite association indicates a critical role for EBV as
a driver of this disease, although a mechanism of T/NK-cell trans-
formation by EBV is not yet clearly described.1
EBV is ubiquitous within the human population where the virus
resides lifelong in memory B cells, typically as an asymptomatic
infection. Despite its widespread prevalence, EBV is an oncogenic
virus responsible for ;200 000 new malignancies annually, usually
of B-cell, epithelial cell, or T/NK-cell origin.18 In malignancy, EBV
displays a predominantly latent form of infection, involving all, or
a subset, of latent genes/transcripts termed EBV nuclear antigens
(EBNA1, 2, 3A, 3B, 3C, and LP), the latent membrane proteins
(LMP1, 2A, and 2B), noncoding EBV-encoded small RNA (EBER)
transcripts and several microRNAs.19 These viral products have
been extensively studied in B-cell and epithelial cell backgrounds
with respect to cellular transformation, induction of proliferation,
and maintenance of cell survival,20 but are less well studied in T/NK
cells. Within ENKTL and CAEBV cells, EBV typically expresses
a latency II restricted gene-expression pattern: EBNA11, LMP11,
and/or LMP2A/B1, in addition to noncoding viral RNAs.19,21-23
Importantly, the major viral oncogene, LMP1, is reportedly expressed
in 73% of ENKTL tumors.24 A key component of LMP1 activity in B
and epithelial cells is that it potently stimulates the NF-kB pathway,
which can lead to upregulation of BCL-2 family prosurvival proteins
BCL-2, MCL-1, and BFL-1.25-27
The intrinsic apoptotic pathway is regulated by the BCL-2 family
where the balance of specific interactions between pro- and
antiapoptotic members decides the fate of a cell. The antiapoptotic
proteins (BCL-2, BCL-XL, BCL-W, MCL-1, and A1/BFL1) prevent
the proapoptotic effector proteins (BAK and BAX) from inducing
mitochondrial outer membrane permeabilzation (MOMP), the point
of no return in apoptosis.28 Upon an apoptotic stimulus, proapop-
totic BH3-only proteins (BIM, PUMA, NOXA, BID, BMF, BIK, BAD,
and HRK) are increased (through transcriptional or posttranscrip-
tional processes), bind with very high affinity to the antiapoptotic
members, and thereby unleash the proapoptotic effectors BAX and
BAK to induce MOMP.29 Select BH3-only proteins can also directly
bind and thereby activate BAX and BAK.29
Deregulation of the intrinsic apoptotic pathway is common in tumor
cells and confers protection from cell death induced by oncogenic
stress or chemotherapy.30 Such deregulation can occur through
increased expression of antiapoptotic BCL-2 proteins (eg, Bcl-2/IgH
chromosomal translocation in follicular B-cell lymphoma) or reduced
expression of proapoptotic members (eg,Bim gene hypermethylation
in Burkitt lymphoma).31-33 This, together with the knowledge that
viral proteins can modulate expression of key cellular BCL-2
proteins,20 led us to speculate that targeting of select BCL-2
prosurvival proteins may offer a novel therapeutic option for ENKTL
patients. Small-molecule inhibitors of BCL-2 prosurvival proteins,
known as BH3-mimetics, have been developed to induce apoptosis
in malignant cells.34 The BCL-2–specific inhibitor, ABT-199 (veneto-
clax), is approved by the US Food and Drug Administration (FDA) for
treatment of chemotherapy-refractory chronic lymphocytic leukemia
(CLL) and acute myeloid leukemia (AML).35,36 Clinical trials have
commenced with 3 MCL-1 targeting BH3-mimetic drugs in hematolog-
ical cancers.37-40 BCL-XL–specific compounds, such as A-1331852,
are less advanced but have shown success in preclinical models.41,42
Such studies, and data from clinical trials with ABT-263/navitoclax,
which targets BCL-XL, BCL-2, and BCL-W, indicate a narrow
therapeutic window for BCL-XL inhibitors due to dose-limiting
on-target thrombocytopaenia.43
Here, we characterize a panel of ENKTL and CAEBV patient-derived
cell lines as appropriate preclinical disease models. Through
in vitro analyses and an in vivo mouse xenograft model, we
demonstrate that therapeutic targeting of BCL-XL alone, or in
combination with MCL-1 inhibition, can have therapeutic efficacy
for EBV-driven T- and NK-cell disease.
Materials and methods
Animal work
Experiments performed with mice were conducted in accordance
with guidelines of The Walter and Eliza Hall Institute Animal Ethics
Committee. Single-cell suspensions of ENKTL/CAEBV cell lines
were delivered to 6- to 8-week-old NOD-SCID-IL2rg2/2 (NSG)
female mice44 by subcutaneous (23 106 cells) or intraperitoneal (5
3 106 cells) injection.
A-1331852, formulated in 60% Phosal 50 PG (Lipoid), 27.5%
polyethylene glycol 400 (Sigma), 10% ethanol, and 2.5% dimethyl
sulfoxide (DMSO) was administered by oral gavage at 50 mg/kg
once daily for 7 consecutive days. Upon fulfillment of end point
criteria, mice were euthanized by CO2 exposure.
Cell lines and cytogenetic analyses
Cell lines SNK6, SNT8, SNT15, SNT16, and MEC0445-48 were
grown in RPMI 1640 medium (Sigma) supplemented with 10%
vol/vol heat-inactivated and sterile-filtered human serum (Sigma),
100 U/mL penicillin (Invitrogen), 100 mg/mL streptomycin (Invitrogen),
6 mM L-glutamine (Invitrogen), 1 mM sodium pyruvate (Sigma),
700 U/mL IL-2 (Novartis). BL-41 and Raji cells were cultured in
RPMI 1640 medium supplemented with 10% vol/vol FCS, 1 mM
glutamine (Invitrogen), 1 mM sodium pyruvate (Sigma), and 50 mM
thioglycerol (Sigma). All T/NK-cell lines were karyotyped as described
in supplemental Methods.
Targeted TP53 gene sequencing
DNA was extracted using the DNeasy Blood and Tissue kit (Qiagen)
according to the manufacturer’s instructions. Amplicon libraries
targeting TP53 exons 2-11 (NM_000546) were prepared using
a 2-step polymerase chain reaction (PCR) approach: first internal
PCR to amplify the regions of interest (supplemental Table 1),
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followed by second outer PCR to add the sequencing adaptors,
and indexes for multiplexing as detailed in supplemental Methods.
Western blotting
Total protein extracts were prepared from cells by lysis using
radioimmunoprecipitation assay (RIPA) buffer containing com-
plete mini protease inhibitor cocktail (Roche). Western blotting
was performed as detailed in supplemental Methods.
Cell-death assays
Cells were exposed to drugs (supplemental Table 3) at the
specified doses, harvested at set time points, and stained with
annexin V (conjugated to fluorescein isothiocyanate [FITC] or Alexa
Fluor 647) and propidium iodide (2 mg/mL) in annexin V binding
buffer (0.1 M N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid
[HEPES; pH 7.4], 1.4 M NaCl, 25 mM CaCl2). Samples were
analyzed in an LSR-II, LSR-Fortessa X-20, or Accuri C6 (BD
Biosciences) flow cytometer and data analyzed using FlowJo 10
(Treestar).
Cell-surface phenotyping
Cells were first stained with viability dye (violet stain) (ThermoFisher)
according to the manufacturer’s instructions and subsequently
stained for surface markers by incubating on ice for 30 minutes with
saturating concentrations of antibodies described in supplemental
Table 4. Cells were analyzed on a LSR Fortessa II (BD Biosciences)
and data were processed using FlowJo software (Treestar).
Rhodamine-123 efflux assay
Expression and functionality of P-glycoprotein was determined by
measuring the relative intensity of cell staining using the fluorescent
molecule rhodamine-123 (Rh-123; Sigma), a P-glycoprotein–
specific substrate, as described in the supplemental Methods.
RNA extraction and cDNA synthesis
RNA was prepared using Nucleospin II kit (Macherey-Nagel) and
DNAse I treated using a DNA-free kit (Life Technologies) and
complementary DNA (cDNA) generated using QScript (VWR),
all according to the manufacturer’s protocols.
Quantitative reverse transcriptase (qRT)–PCR
analysis for EBV transcripts
Absolute quantification of EBV gene transcripts by high throughput
quantitative PCR was performed using the Fluidigm Dynamic Array
system as previously described49 and detailed in supplemental
Methods.
CRISPR/Cas9 gene editing
CRISPR/Cas9-induced knockout of MCL-1 in MEC04 cells
was induced using an inducible lentiviral guide RNA system
as previously described.50 Sequences of single-guide RNAs
(sgRNAs) are as follows: human MCL-1 exon 1, 59-GGGAGG
GCGACTTTTGGCTA; mouse Bim exon 2 (control sgRNA), 59-
GAGCGCTGCTCCGATGGTGA.
Statistical analysis
Prism software (GraphPad) was used to perform statistical tests
with P , .05 considered significant. Data presented are means
of 3 independent experiments unless stated otherwise. Error bars
indicate the standard deviation or standard error as indicated in
figure legends.
Results
Characterizing EBV1 T- and NK-cell lines
Although reports assessing patient samples have been published,
it should be noted that general availability of primary material is
extremely limited.51,52 Due to the rarity of EBV-driven T- and NK-cell
lymphoproliferative diseases and the difficulties to derive immortal-
ized cell lines, attributed to the necrotic nature of ENKTL tumors,
most functional studies described within the literature have focused
on only a subset of the few available ENKTL and CAEBV cell lines.
Here, we characterize a comprehensive collection of 3 ENKTL
cells lines (SNK6, SNT8, and MEC04) and 2 CAEBV cell lines
(SNT15 and SNT16), to determine how closely they represent
these diseases.45-48
Consistent with their reported NK-cell phenotype, all cells within
SNK6 and MEC04 cell populations expressed CD56 (supplemental
Figure 1). As expected, SNT8 and SNT15 cells were positive for
TCR Vd2, however, SNT15 cells were CD562. The CAEBV cell line
SNT16, was of CD4 T-cell lineage, as reported.47 All cell lines
require interleukin 2 (IL-2) for continued proliferation in vitro
and, accordingly, they all expressed the IL-2 receptor a chain
(CD25), although MEC04 cells expressed comparatively low
levels.
EBV gene expression was quantified by absolute qRT-PCR assays.
Transcripts specific for latent EBNA1 and LMP2 were detected in
all cell lines (Figure 1A). Transcripts and LMP1 protein (revealed by
western blotting) could only be detected in SNK6, SNT8, and
SNT16 cells (Figure 1B). The absence of EBNA2 transcripts and
protein in all cell lines indicated a latency II viral gene-expression
pattern (Figure 1B). Lytic cycle-associated transcripts could be
detected at low levels in all cell lines, with the highest level of
BZLF1, a lytic cycle transcriptional activator, detected in SNT16
cells at 0.0665 transcripts per phosphoglycerate kinase (PGK;
Figure 1A). In a 100% lytic cellular population, the expected level
of BZLF1 exceeds 9 copies per PGK,49 suggesting the levels
observed in the T/NK-cell lines are a consequence of spontaneous
abortive EBV lytic activation in rare cells, a common phenomenon in
EBV1 cell lines.19 The apparent latency II gene-expression pattern
and lack of lytic activity observed within the T/NK-cell line panel is
comparable to patient CAEBV and ENKTL samples.53
Resistance to cytotoxic agents is not universally
mediated by MDR1 activity or TP53 mutations
Considering the apparent lack of response to standard-of-care
chemotherapeutic drugs in ENKTL patients, we may expect that
ENKTL and perhaps CAEBV-derived cell lines will display resis-
tance to such compounds in vitro. Following a 48 hours treatment
with etoposide, 2 cell lines (SNK6 and SNT16) exhibited high
resistance to apoptosis (50% inhibitory concentration [IC50]
values. 10 mM) and the remaining cell lines (SNT8, SNT15, and
MEC04) exhibited moderate resistance (IC50 values of 1.9 mM,
3.3 mM, and 7.2 mM, respectively) (Figure 2A). Similarly, methotrexate
treatment had only modest impact, with 4 of 5 cell lines displaying
high levels of resistance (IC50 values. 10 mM) (Figure 2B). In fact,
even for MEC04 cells, that had comparable IC50 values to the
susceptible control cell line MOLT4 (1.2 mMand 1.1mM, respectively),
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there remained 42.3% viability at the highest tested concentration
(10 mM), compared with only 6.1% for MOLT4 cells. This indicates
that a significant proportion of the MEC04 cell population were
highly resistant to methotrexate. These drugs act through TP53 but
sequencing revealed wild-type TP53 sequences in all cell lines, with
the exception of MEC04 that had a c.743G.A (p.Arg248Gln) point
mutation in exon 7 (Table 1).
MDR1 expression has been proposed to be responsible for
chemotherapy resistance in ENKTL tumors.4,5 To examine this,
MDR1 activity was assessed by efflux of the MDR1-specific
substrate rhodamine-123 in the ENKTL and CAEBV cell lines.
Rhodamine-123 efflux was observed in the NK-ENKTL cell lines
SNK6 and MEC04, but absent in the T-ENKTL cell line, SNT8, and
in both CAEBV cell lines (Figure 2C). Collectively, these data indicate
that neither MDR1 activity nor TP53 mutations were consistent
mediators of the observed resistance of EBV1 T- and NK-cell
lines to genotoxic anticancer agents.
BCL-XL–specific BH3-mimetic drugs consistently
induced apoptosis in ENKTL and CAEBV cell lines
Downstream of TP53, the intrinsic apoptotic pathway must be
functional for induction of cell death by genotoxic agents. Expression
of prosurvival proteins BCL-2, BCL-XL, and MCL-1 were universally
detected, where BCL-2 showed the most consistent expression in
the panel of ENKTL and CAEBV cell lines examined (Figure 3A).
Proapoptotic BIM and BID expression was absent or low in most cell
lines relative to the control cell line BL41. The proapoptotic effectors,
BAK and BAX, were universally expressed. Taken together, the
expression data indicate that theoretically all cell lines should be
capable of undergoing intrinsic apoptosis.
The sustained growth and survival of several cancers has been
attributed to reliance on 1 or more of the prosurvival proteins,
BCL-2, BCL-XL, and MCL-1.36,54-58 To investigate this in the context
of ENKTL and CAEBV, cell lines were treated with various BH3-
mimetic drugs (Figure 3B). Despite universal expression of BCL-2,
the cell lines were resistant to treatment with the BCL-2–specific
inhibitor ABT-199. They displayed similar resistance to the MCL-1
inhibitor S63845, with the exception of the SNT15 cells. The greatest
sensitivity observed across all cell lines was for treatment with the
BCL-XL–specific compound, A-1331852. Accordingly, ABT-737,
which targets BCL-XL, BCL-2, and BCL-W, also induced apoptosis
across the cell line panel, consistent with the EBV1 T/NK-cell lines
being BCL-XL dependent. Interestingly, the sensitivity to BCL-XL
inhibition was independent of whether the cell lines expressed
viral LMP1.
The BCL-XL inhibitor A-1331852 delays tumor growth
in ENKTL-engrafted NSG mice
As A-1331852 has been demonstrated to be bioavailable in animal
models of breast, ovarian and small cell lung cancer,41 we examined
its impact on tumor growth in in vivo models of ENKTL and CAEBV.
SNK6, SNT15, and MEC04 cells were either subcutaneously or
intraperitoneally injected into NOD-SCID-IL2rg2/2 (NSG) recipient
mice followed by daily treatments with 50 mg/kg A-1331852 for
7 days. In NSG mice intraperitoneally injected with SNK6 cells
(SNK6-IPmice), a significant delay in tumor development was observed
after treatment with A-1331852 compared with vehicle-treated mice,
with median tumor latencies of 56 days and 37 days posttransplant,
respectively (P 5 .0002) (Figure 4A). Similarly, in SNK6-SC–bearing
mice, A-1331852 treatment significantly delayed tumor growth (median
tumor latency of 56 days compared with vehicle-treated mice (37 days)
(P 5 .022)) (Figure 4B). In contrast, A-1331852 was ineffective
at delaying tumor growth in mice transplanted with SNT15 cells
(Figure 4C) or MEC04 cells (Figure 4D). Following drug treatment
(day 14), there was a marked decrease in platelet numbers, consis-
tent with successful administration of the drug with BCL-XL inhibition
causing on-target thrombocytopenia (Figure 4A,D).59 As expected, the
platelet counts rebounded to pretreatment levels by the time of sacrifice
(days 34-62 posttransplant). Unfortunately, we were unable to assess
the efficacy of BCL-XL inhibition in tumor growth using SNT8 and
SNT16 cells as they did not reliably grow as xenografts in NSG mice.
IL-2 deprivation results in a reduction in BCL-XL levels
and an increase in MCL-1 expression
Following xenotransplantation of SNT15 and MEC04 cells (Figure



























































































Figure 1. EBV displays a latency II gene-expression pattern in ENTKL- and
CAEBV-derived cell lines. (A) Heatmap summary of EBV transcript levels to
compare between the different cell lines. Data shown were normalized to the levels
of PGK1 transcripts. (B) Expression levels of key viral proteins, LMP1 and EBNA2,
at steady state were assessed by western blot analysis. Probing for HSP70 was
used as a protein loading control and BL cell lines, BL41 and Raji, and
a lymphoblastoid cell line (LCL) were included as controls. Representative blots
are shown.
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treatment despite the marked sensitivity of these cells to this
compound in vitro (Figure 3B). In vitro all ENKTL and CAEBV
cell lines require exogenous IL-2 for continued survival and
growth (Figure 5A). We speculated that the restricted IL-2
availability in NSG mice, due to the absence of IL-2–producing
lymphocytes in this model, may have impacted the expression of
BCL-2 family proteins. Therefore, to mimic the in vivo setting, we
deprived cells of IL-2 for 48 hours in vitro, then assessed BCL-2
family protein expression. BIM expression increased in SNT15
and MEC04 (the only BIM-expressing cell lines) indicating
that cells were responding to cytokine deprivation. Importantly,
BCL-XL expression decreased in the absence of IL-2 (Figure 5B),
whereas MCL-1 expression increased in all cell lines (Figure 5B;
supplemental Figure 2).
MCL-1 compensates for inhibition or downregulation
of BCL-XL
BCL-XL was identified as the primary survival factor in ENKTL and
CAEBV cells and its expression was changed by IL-2 withdrawal.
We hypothesized that at least for SNT15 and MEC04 cells that























































































































































































































Figure 2. Resistance to common chemotherapeutic drugs in ENKTL and CAEBV cell lines is not only due to P-glycoprotein–mediated drug efflux. Dose-
response curves generated from annexin V/propidium iodide (PI) staining assays following 48-hour treatment with etoposide (A) or methotrexate (B) at the indicated concen-
trations. (C) The functionality of P-gp was assessed by the efflux of fluorescent rh-123 using flow cytometry. Cells were either left unstained or stained with rh-123 (black,
filled histogram), stained with subsequent incubation at 4°C (gray, filled histogram), stained with subsequent incubation at 37°C (red, open histogram) or stained with
subsequent incubation at 37°C in the presence of the P-gp inhibitor, CsA (blue, open histogram). (D) Rh-123 efflux was quantified using the following formula:
(MFIred 3 100) / (MFIgray 2 MFIblack). KG-1 cells (positive control) and Jurkat cells (negative control) were included in the experiments due to their reported high P-gp
expression and lack of P-gp expression, respectively. Data are presented as means 6 standard deviation (SD) of 3 independent experiments, each performed in triplicate
(n 5 3). ***P , .0001, vs Jurkat. CsA, cyclosporin A; MFI, median fluorescence intensity; P-gp, P-glycoprotein.
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and possibly for other cell lines also, a secondary factor must also
contribute to survival in circumstances where BCL-XL is low/inhibited.
Furthermore, IL-2 withdrawal led to a slow, rather than immediate,
death of cells over many days after the initial decrease in BCL-XL
expression and for some cell lines the viability then stabilized. To
identify the secondary survival factor(s), BH3-mimetic drug treatment
of SNK6, SNT15, and MEC04 cells was performed after 48 hours
of culture in medium lacking IL-2 leading to reduced levels of
BCL-XL. As in vivo, SNK6 cells maintained comparable sensitivity to
A-1331852 in vitro when deprived of IL-2 (Figure 6A). In contrast,
SNT15 cells displayed decreased sensitivity to A-1331852 in
medium lacking IL-2 (Figure 6B), an observation in agreement with
their in vivo resistance to BCL-XL inhibitor treatment (Figure 4D).
MEC04 cells showed a trend toward increased sensitivity to
A-1331852 following IL2 withdrawal, however this was not
statistically significant (Figure 6C). Notably, a significant increase in
sensitivity to the MCL-1 inhibitor S63845 was observed in both
SNT15 and MEC04 cells when cultured without IL-2. This suggests
that these cells display a dependency on MCL-1 under such stress
Table 1. Summary of EBV latency, LMP1 status, and TP53 status in
ENKTL and CAEBV cells
Cell line EBV latency LMP1 status TP53 status
SNK6 II 1 Wild type
SNT8 II 1 Wild type
SNT15 II 2 Wild type
SNT16 II 1 Wild type



















































































































Figure 3. BH3-mimetic drugs targeting BCL-XL induce cell death in ENKTL and CAEBV cell lines. (A) Expression levels of cellular BCL-2, BCL-XL, MCL-1, BIM,
PUMA, NOXA, BAK, and BAX were detected by western blot analysis. Probing for HSP70 was used as a protein loading control. The Burkitt lymphoma–derived cell lines,
BL41 and Raji, and LCL were used as controls. Representative blots are shown. (B) Cells were treated for 48 hours with 0.5 mM or 5 mM of the indicated BH3-mimetic drugs
ABT-199 (BCL-2 specific), ABT-737 (inhibits BCL-2, BCL-XL, and BCL-W), A-1331852 (BCL-XL specific), or S63845 (MCL-1 specific). Cells were then stained with annexin
V and PI and their viability quantitated by flow cytometry. Data shown are normalized to DMSO-treated control cells and presented as mean 6 SD of 3 independent
experiments.
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conditions. Consistently, the combined in vitro treatment of A-1331852
with S63845 proved the most potent inducer of apoptosis in
SNK6, SNT15 and MEC04 cells relative to other combinations of
BH3-mimetics (Figure 6D). This further suggests that MCL-1
plays a critical role alongside BCL-XL in sustaining the survival of
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Figure 4. The BCL-XL–specific BH3-mimetic drug A-1331852 inhibits tumor growth in NSG mice that had been transplanted with SNK6 cells. NSG mice were
injected subcutaneously (SC) or intraperitoneally (IP) with SNK6, SNT15, or MEC04 cells on day 0. From day 7, A-1331852 or vehicle were delivered once daily to mice by
oral gavage for 7 consecutive days. Mice were then monitored for tumor burden. Platelet levels in peripheral blood were examined pretreatment (day 7), posttreatment (day 14),
and immediately prior to euthanization. NSG mice were injected intraperitoneally with SNK6 cells (5 3 106 cells) (A), subcutaneously with SNK6 cells (2 3 106 cells) (B),
subcutaneously with SNT15 cells (2 3 106 cells) (C), or intraperitoneally with MEC04 cells (5 3 106 cells) (D). Mouse survival curves were assessed for significant differences
by the Mantel-Cox test. Platelet and tumor weight data are shown with mean 6 standard error (SE), and statistical significance were determined by unpaired Student t test.
*P , .05; ***P , .0001. ND, not done.




 http://ashpublications.org/bloodadvances/article-pdf/4/19/4775/1760443/advancesadv2020002446.pdf by guest on 13 O
ctober 2020
Cell death induced by BCL-XL–specific BH3-mimetics
is enhanced by loss of the MCL-1 gene
To examine the hypothesis that optimal killing of T/NK tumors
would be achieved by inhibition of both BCL-XL and MCL-1,
CRISPR/Cas9-mediated mutations of MCL-1 were induced in
MEC04 cells. Western blot analysis of single cell clones confirmed
successful loss of MCL-1 in clones #4, #13, and #22 (Figure 7A).
Clones #107, #108, and #109 retained MCL-1 expression as
these control cells had instead been transduced with a nontargeting
sgRNA. In support of the above hypothesis, MEC04 cells lacking wt
MCL-1 could not form tumors in NSG mice (data not shown). Such
cells were instead assessed in vitro for survival following treatment
with A-1331852, ABT-199 or S63845 (Figure 7B-D). As predicted,
MCL-1-depleted MEC04 cells were more sensitive to A-1331852,
as the mean IC50 value had decreased 378-fold compared with
control cells containing the nontargeting sgRNA (Figure 7E).
Perhaps surprisingly, MEC04 cells lacking MCL-1 were sensitized
to ABT-199, albeit only at high concentrations. The data further
confirm that MCL-1 behaves as the secondary survival factor when
BCL-XL action is restricted.
Discussion
ENKTL disease responds poorly to chemotherapy regimens,
including CHOP and SMILE,6-8 which initiate apoptosis through DNA
damage–induced upregulation of the BH3-only proteins PUMA and
NOXA.60 Relapse is common and the median overall survival for patients
is only 7.8 months,3 highlighting a need for alternative therapies.
One factor limiting progress for improved therapy is the shortage of
accurate cell line models for study. The EBV1 T/NK-cell lines used
here were confirmed as representative ENKTL/CAEBV disease
models by way of their immunophenotype and EBV gene expression.
They are therefore suitable models for testing therapeutic vulner-
abilities. The inclusion of both LMP11 and LMP12 cell lines captured
the diversity of EBV gene-expression patterns observed within clinical
samples.24 In accordance with the poor effectiveness of the SMILE
chemotherapy regimen, all ENKTL/CAEBV cell lines examined
exhibited low susceptibility to both etoposide and methotrexate.
This resistance could not be correlated to P-glycoprotein activity
or the TP53 status, suggesting that other resistance factors were
responsible.
We postulated that inducing apoptosis at a point further down-
stream in the pathway by using novel BH3-mimetic drugs could be
an effective therapy for EBV-associated NK-/T-cell tumors. Initially,
we anticipated that this therapy may only be effective for those
tumors that express LMP1 because LMP1 expression has been
shown to upregulate levels of the cellular prosurvival proteins,
BCL-2, MCL-1, and BFL-1.25-27 Although BH3-mimetic drugs
targeting BCL-2 and MCL-1 were largely ineffective, those that
inhibit BCL-XL (A-1331852 and ABT-737) induced substantial cell
death in all ENKTL and CAEBV cell lines examined in vitro, irrespective
of LMP1 status, indicating a primary survival dependency on BCL-XL.
Notably, A-1331852 treatment markedly delayed tumor expansion
in an SNK6 xenotransplant mouse model of ENKTL. However, this
was not achieved in xenografts of SNT15 or MEC04 cells, and we
speculated that this was due to IL-2 deprivation of these malignant
cells in NSG mice that do not contain any mature CD41 T cells, the
major source of IL-2.44,61 We therefore predicted that this change
in IL-2 availability would alter the expression of key BCL-2 family
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Figure 5. IL-2 withdrawal leads to loss of viability
and reduced BCL-XL expression in ENKTL cell
lines. (A) ENKTL cells cultured in medium lacking IL-2
were assessed over a 120-hour time course by flow
cytometry for viability as determined by annexin V plus PI
staining. Data were normalized to cell viability of cells
grown in medium supplemented with IL-2 and are pre-
sented as means 6 SD of 3 independent experiments,
each performed in triplicates (n 5 3). (B) Expression lev-
els of BCL-XL, MCL-1, and BIM proteins were detected
by western blot analysis in cells cultured in medium lack-
ing IL-2 (in the presence of the broad-spectrum caspase
inhibitor QVD-OPH [25 mM] to prevent late stages of
apoptosis with cell demolition) at the indicated time
points. Probing for HSP70 was used as a protein load-
ing control. Representative blots are shown.
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the levels of BCL-XL decreased upon IL-2 deprivation and, of
note, in SNT15 as well as MEC04 cells, MCL-1 levels increased.
This resulted in SNT15 cells becoming less sensitive to the
BCL-XL inhibitors and more sensitive to the MCL-1 inhibitor.
Although these experiments revealed limitations in in vivo
xenotransplant models for investigations into ENKTL, they
also gave insights into resistance factors that would come into
play when BCL-XL expression was inhibited. Specifically, our
results indicate that MCL-1 expression may be a potential
resistance factor in patients treated with BCL-XL targeting
BH3-mimetics.
In agreement with this, in vitro studies suggested that the
most efficacious pairing of BH3-mimetics for the treatment
of ENKTL cell lines was BCL-XL inhibition in combination with
MCL-1 inhibition. Consistently, in MEC04 cells, the genetic
loss of MCL-1 enhanced the efficacy of A-1331852. The reason
why SNK6 cells retain sensitivity to A-1331852 in vivo remains
unknown but this may be due to the relatively high levels of
BCL-XL expression at steady state in these cells. One hypoth-
esis is that the relatively high expression of LMP1 in SNK6 cells
could be maintaining sufficient BCL-XL dependency through
a strong induction of NF-kB signaling, a pathway known to
regulate BCL-XL.62,63
Moving forward, our data suggest that targeting BCL-XL, either
directly using BH3-mimetic drugs or indirectly by reducing the
expression of BCL-XL through, for example, IL-2 restriction in patients,
could be an effective therapeutic strategy for EBV-associated CAEBV
and ENKTL. The dependency of platelets on BCL-XL for survival,
as was shown in the early clinical trials of navitoclax/ABT-263,
which targets BCL-XL, BCL-2, and BCL-W, in patients with
lymphoid malignancies or small cell lung cancer,59 will necessitate
careful clinical management or targeted delivery of drugs to cancer
cells, perhaps by conjugating them to antibodies that bind to the
malignant cells. One such antibody-drug conjugate derived from
a BCL-XL inhibitor, ABBV-155, is under early clinical investigation
as both a monotherapy and in combination with taxane therapy
(NCT03595059). Additionally, a platelet-sparing PROTAC degrader
of BCL-XL, DT2216, has recently been developed as a better
tolerated alternative to navitoclax/ABT-263.64 Our data further
indicate that resistance to BCL-XL inhibitors may be mediated
by MCL-1 expression, suggesting that dual targeting of both
BCL-XL and MCL-1 might provide a more efficacious therapy.
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Figure 6. Sensitivity of ENKTL cell lines to the MCL-1 inhibitor S63845 increases upon IL-2 withdrawal or treatment with the BCL-XL inhibitor A-1331852.
SNK6 (A), SNT15 (B), and MEC04 (C) cells were cultured in medium lacking IL-2 for 48 hours and were then treated with either 0.5 mM or 5 mM of the indicated
BH3-mimetic drugs. Cell viability was determined by flow cytometry after staining with annexin V plus PI and data were normalized to DMSO-treated controls or
DMSO-treated IL-2 deprived cells as appropriate. (D) Cell viability was determined after treatment with the BCL-XL inhibitor A-1331852 alone or in combination with
either the BCL-2 inhibitor ABT-199 or the MCL-1 inhibitor S63845. Cell viability was determined by flow cytometry after staining with annexin V plus PI and data were
normalized to DMSO-treated control cells. All compounds were used at a final concentration of 5 mM. Data in panels A and B are presented as means 6 SD of
3 independent experiments, each performed in triplicates (n 5 3). Significance was determined by the unpaired Student t test and corrected for multiple comparisons
using the Holm-Sidak method. *P , .05; **P , .001.




 http://ashpublications.org/bloodadvances/article-pdf/4/19/4775/1760443/advancesadv2020002446.pdf by guest on 13 O
ctober 2020
Pharmacological inhibition of multiple prosurvival BCL-2 proteins
will be challenging due to on-target toxicity to healthy cells but
has been achieved for BCL-2 and MCL-1 by using 2 BH3-mimetic
drugs in animal models of mantle cell lymphoma, T-cell acute
lymphoblastic leukemia, and AML.65-67 In fact, for the treatment
of AML, the combination of BCL-2 and MCL-1 inhibition by
BH3-mimetics has reached phase 1 clinical trials (NCT03672695).
For the combined targeting of BCL-XL andMCL-1 using BH3-mimetics,
a tolerable treatment regimen in mouse models has not yet been
achieved. One strategy would be to combine BH3-mimetic drugs
targeting MCL-1 (which are already in clinical trials), with drugs
that target upstream regulators of BCL-XL, such as NF-kB
inhibitors.
The lack of efficacy of chemotherapy regimens in ENKTLmalignancies,
























































































































































Figure 7. Loss of MCL-1 enhances killing of MEC04 cells by the BCL-XL inhibitor A-1331852 and sensitizes these cells to high doses of the BCL-2 inhibitor
ABT199. (A) MEC04 cells stably expressing Cas9 were infected with doxycycline-inducible sgRNAs targeting either human MCL-1 (isgMCL-1_hEx1) or mouse Bcl2l11(Bim)
(nontargeting control) (isgNT). Cells were single cell sorted by flow cytometry following doxycycline treatment and then examined for MCL-1 expression by western blot
analysis. Dose-response curves generated from annexin V/PI assays following 24-hour treatment with A-1331852 (B), ABT199 (C), or S63845 (D) at the indicated concen-
trations. (E) IC50 values generated from dose-response curves were grouped by genotype and compared for each drug treatment. Data are presented as means 6 SD of
3 independent experiments, each performed in triplicate (n 5 3). Significance was determined by the unpaired Student t test and corrected for multiple comparisons using the
Holm-Sidak method. **P , .001.
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presented here, mandates that novel options become available.
The recent use of BH3-mimetic drugs as effective treatments for
various blood cancers suggests that such therapies may also be
suitable for patients suffering from an EBV-driven proliferation of
T/NK cells.
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